Clinical Trial

Functional Connectivity of the Interoceptive Network in RLS

Study acronym: IntoRLS
Recruiting
View on ClinicalTrials.gov →
Summary
Restless Legs Syndrome (RLS) is a sensorimotor disorder primarily characterized by an irresistible urge to move the legs while at rest. A key hypothesis suggests that RLS symptoms are linked to abnormal brain function in processing internally generated stimuli, particularly interoception. This distorted perception of the internal bodily state leads to maladaptive behaviors, which may manifest across a wide range of medical and psychiatric disorders. Here, the investigators hypothesize that dysfunction in the insular cortex (IC) may result in a failure of behavioral adaptation, primarily expressed as an urge to move the legs and hyperarousal, even when the body and mind need rest. This project aims to assess the relationship between interoceptive abilities and diurnal fluctuations in IC functional connectivity (FC) in patients with RLS compared to healthy controls. The investigators will also examine correlations between the FC of the interoceptive network, measured in the morning and evening on the same day, using multilayer network analysis, daily fluctuations in RLS symptom severity, and objective measurements of the sleep/wake cycle, gathered through a two-week ambulatory assessment using mobile technologies such as Ecological Momentary Assessment (EMA) and actigraphy, along with scores from self-reported questionnaires. The findings may provide strong evidence to support or refute the hypothesis of interoceptive dysfunction in RLS patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-23.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT07001891
Lead Sponsor University Hospital, Bordeaux
Collaborators: Restless Legs Syndrome Foundation
Conditions Restless Legs Syndrome
Enrollment 30 participants
Start Date 2025-09-16
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-17